• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

European Pharma and Biotech Looking Outside EU for Funding


November 10, 2015.

The European Union remains a "powerhouse of innovation" for biotech and pharma, but mostly looks the the US for funding, according to a new report from BioPharm Insight.

Fuelling the growth of EU Pharma and Biotech states that

  • Although trials have dropped by 24% since 2010, sector innovation is high, led by innovations in oncology drugs, neurological agents and gene therapy treatments.

  • Deal activity is up in 2015 to date, with increasing interest from European investors; however, three out of top five IPOs listed outside the EU.

  • Deeper pools of capital and specialist investors are key factors attracting biotech and pharma to US for funding.

  • EU biotechs are exploring a wide spectrum of funding opportunities, including crowdfunding, grant funding and secondary listings.                  

Copies of the report can be obtained by contacting pressenquiries@mergermarketgroup.com 

Related Videos